ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Estrella Immunopharma, Inc.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.38−0.05 (-11.65%)
Close on Oct 19, 2026
- Market cap
- $16.17M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Estrella Immunopharma has not reported a dividend
No dividend per share appears in Estrella Immunopharma's annual filings since fiscal 2020.